Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 179368, 14 pages
http://dx.doi.org/10.1155/2014/179368
Research Article

MSH Blunts Endotoxin-Induced MuRF1 and Atrogin-1 Upregulation in Skeletal Muscle by Modulating NF-B and Akt/FoxO1 Pathway

Department of Physiology, Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain

Received 13 June 2014; Accepted 20 August 2014; Published 9 September 2014

Academic Editor: Alex Kleinjan

Copyright © 2014 Ana Isabel Martín et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Callahan and G. S. Supinski, “Sepsis-induced myopathy,” Critical Care Medicine, vol. 37, no. 5, pp. S354–S367, 2009. View at Google Scholar
  2. J. B. Poulsen, K. Møller, C. V. Jensen, S. Weisdorf, H. Kehlet, and A. Perner, “Effect of transcutaneous electrical muscle stimulation on muscle volume in patients with septic shock,” Critical Care Medicine, vol. 39, no. 3, pp. 456–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Klaude, M. Mori, I. Tjäder, T. Gustafsson, J. Wernerman, and O. Rooyackers, “Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis,” Clinical Science, vol. 122, no. 3, pp. 133–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kovarik, T. Muthny, L. Sispera, and M. Holecek, “The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle,” Journal of Physiology and Biochemistry, vol. 68, no. 3, pp. 385–395, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. Lecker, R. T. Jagoe, A. Gilbert et al., “Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression,” FASEB Journal, vol. 18, no. 1, pp. 39–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Pijet, M. Pijet, A. Litwiniuk, M. Gajewska, B. Pajak, and A. Orzechowski, “TNF-α and IFN-s-dependent muscle decay is linked to NF-κB- and STAT-1α-stimulated Atrogin1 and MuRF1 genes in C2C12 myotubes,” Mediators of Inflammation, vol. 2013, Article ID 171437, 18 pages, 2013. View at Publisher · View at Google Scholar
  7. M. Sandri, C. Sandri, A. Gilbert et al., “Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy,” Cell, vol. 117, no. 3, pp. 399–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Reed, P. B. Sandesara, S. M. Senf, and A. R. Judge, “Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy,” FASEB Journal, vol. 26, no. 3, pp. 987–1000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Nystrom and C. H. Lang, “Sepsis and AMPK activation by AICAR differentially regulate FoxO-1, -3 and -4 mRNA in striated muscle,” International Journal of Clinical and Experimental Medicine, vol. 1, pp. 50–63, 2008. View at Google Scholar
  10. I. J. Smith, N. Alamdari, P. O'Neal, P. Gonnella, Z. Aversa, and P.-O. Hasselgren, “Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 5, pp. 701–711, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Fan, D. Char, A. J. Kolasa et al., “Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin,” The American Journal of Physiology, vol. 269, no. 1, pp. E33–E42, 1995. View at Google Scholar · View at Scopus
  12. L. Soto, A. I. Martín, S. Millán, E. Vara, and A. López-Calderón, “Effects of endotoxin lipopolysaccharide administration on the somatotropic axis,” Journal of Endocrinology, vol. 159, no. 2, pp. 239–246, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Priego, I. Ibáñez de Cáceres, A. I. Martín, M. A. Villanúa, A. López-Calderón, and I. Ibáñez de, “Glucocorticoids are not necessary for the inhibitory effect of endotoxic shock on serum IGF-I and hepatic IGF-I mRNA,” Journal of Endocrinology, vol. 172, no. 3, pp. 449–456, 2002. View at Google Scholar
  14. P.-O. Hasselgren, N. Alamdari, Z. Aversa, P. Gonnella, I. J. Smith, and S. Tizio, “Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylation,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 4, pp. 423–428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Schakman, S. Kalista, C. Barbé, A. Loumaye, and J. P. Thissen, “Glucocorticoid-induced skeletal muscle atrophy,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 10, pp. 2163–2172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Castillero, N. Alamdari, S. H. Lecker, and P.-O. Hasselgren, “Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes,” Metabolism: Clinical and Experimental, vol. 62, no. 10, pp. 1495–1502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Sacheck, A. Ohtsuka, S. C. McLary, and A. L. Goldberg, “IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 287, no. 4, pp. E591–E601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. T. N. Stitt, D. Drujan, B. A. Clarke et al., “The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors,” Molecular Cell, vol. 14, no. 3, pp. 395–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Gonindard, C. Goigoux, E. Hollande, and L. D. D'Hinterland, “The administration of an α-MSH analogue reduces the serum release of IL-1α and TNFα induced by the injection of a sublethal dose of lipopolysaccharides in the BALB/c mouse,” Pigment Cell Research, vol. 9, no. 3, pp. 148–153, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Brzoska, T. A. Luger, C. Maaser, C. Abels, and M. Böhm, “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases,” Endocrine Reviews, vol. 29, no. 5, pp. 581–602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. K. Manna and B. B. Aggarwal, “α-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-κB activation induced by various inflammatory agents,” The Journal of Immunology, vol. 161, no. 6, pp. 2873–2880, 1998. View at Google Scholar · View at Scopus
  22. S.-N. Lee, J.-H. Ryu, J.-H. Joo et al., “α-Melanocyte-stimulating hormone inhibits tumor necrosis factor α-stimulated MUC5AC expression in human nasal epithelial cells,” The American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 5, pp. 716–724, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Chiao, S. Foster, R. Thomas, J. Lipton, and R. A. Star, “α-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation,” Journal of Clinical Investigation, vol. 97, no. 9, pp. 2038–2044, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Rajora, G. Boccoli, A. Catania, and J. M. Lipton, “α-MSH modulates experimental inflammatory bowel disease,” Peptides, vol. 18, no. 3, pp. 381–385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Ceriani, J. Diaz, S. Murphree, A. Catania, and J. M. Lipton, “The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats,” Neuroimmunomodulation, vol. 1, no. 1, pp. 28–32, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. A. B. Gómez-SanMiguel, A. I. Martín, M. P. Nieto-Bona et al., “Systemic α-melanocyte-stimulating hormone administration decreases arthritis-induced anorexia and muscle wasting,” The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 304, no. 10, pp. R877–R886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Granado, A. I. Martín, T. Priego, M. A. Villanúa, and A. López-Calderón, “Inactivation of Kupffer cells by gadolinium administration prevents lipopolysaccharide-induced decrease in liver insulin-like growth factor-I and IGF-binding protein-3 gene expression,” Journal of Endocrinology, vol. 188, no. 3, pp. 503–511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. M. Miranda, M. G. Espey, and D. A. Wink, “A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite,” Nitric Oxide—Biology and Chemistry, vol. 5, no. 1, pp. 62–71, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. Q.-H. Huang, V. J. Hruby, and J. B. Tatro, “Role of central melanocortins in endotoxin-induced anorexia,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 276, no. 2, pp. R864–R871, 1999. View at Google Scholar · View at Scopus
  30. J. F. Wilson, “Low permeability of the blood-brain barrier to nanomolar concentrations of immunoreactive alpha-melanotropin,” Psychopharmacology, vol. 96, no. 2, pp. 262–266, 1988. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Caruso, C. Mohn, A. L. Karara et al., “Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats,” Neuroendocrinology, vol. 79, no. 5, pp. 278–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. B. Cragnolini, M. Perelló, H. B. Schiöth, and T. N. Scimonelli, “α-MSH and γ-MSH inhibit IL-1β induced activation of the hypothalamic-pituitary-adrenal axis through central melanocortin receptors,” Regulatory Peptides, vol. 122, no. 3, pp. 185–190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Rivier, R. Chizzonite, and W. Vale, “In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1,” Endocrinology, vol. 125, no. 6, pp. 2800–2805, 1989. View at Publisher · View at Google Scholar · View at Scopus
  34. Q.-H. Huang, V. J. Hruby, and J. B. Tatro, “Systemic α-MSH suppresses LPS fever via central melanocortin receptors independently of its suppression of corticosterone and IL-6 release,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 275, no. 2, pp. R524–R530, 1998. View at Google Scholar · View at Scopus
  35. C. Papastathi, A. Mavrommatis, S. Mentzelopoulos, E. Konstandelou, M. Alevizaki, and S. Zakynthinos, “Insulin-like Growth Factor I and its binding protein 3 in sepsis,” Growth Hormone and IGF Research, vol. 23, no. 4, pp. 98–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Priego, M. Granado, I. Ibáñez de Cáceres, A. I. Martín, M. A. Villanúa, and A. López-Calderón, “Endotoxin at low doses stimulates pituitary GH whereas it decreases IGF-I and IGF-binding protein-3 in rats,” Journal of Endocrinology, vol. 179, no. 1, pp. 107–117, 2003. View at Google Scholar
  37. T. Priego, I. Ibáñez de Cáceres, A. I. Martín, M. A. Villanúa, and A. López-Calderón, “Endotoxin administration increases hypothalamic somatostatin mRNA through nitric oxide release,” Regulatory Peptides, vol. 124, no. 1–3, pp. 113–118, 2005. View at Publisher · View at Google Scholar
  38. A. Lelbach, J.-G. Scharf, and G. Ramadori, “Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6,” Journal of Hepatology, vol. 35, no. 5, pp. 558–567, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Priego, I. Ibáñez de Cáceres, A. I. Martín, M. A. Villanúa, and A. López-Calderón, “Endotoxin decreases serum IGFBP-3 and liver IGFBP-3 mRNA: comparison between Lewis and Wistar rats,” Molecular and Cellular Endocrinology, vol. 199, no. 1-2, pp. 23–28, 2003. View at Google Scholar
  40. A. I. Martín, M. López-Menduiña, E. Castillero, M. Granado, M. A. Villanúa, and A. López-Calderón, “Cyclooxygenase-2 activation by endotoxin mediates the decrease in IGF1, but not in IGFBP3, gene expression in the liver,” Journal of Endocrinology, vol. 198, no. 2, pp. 385–394, 2008. View at Google Scholar
  41. E. M. Zimmermann, L. Li, E. C. Hoyt, J. B. Pucilowska, S. Lichtman, and P. K. Lund, “Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 278, no. 3, pp. G447–G457, 2000. View at Google Scholar · View at Scopus
  42. I. A. Malik, J. Triebel, J. Posselt et al., “Melanocortin receptors in rat liver cells: change of gene expression and intracellular localization during acute-phase response,” Histochemistry and Cell Biology, vol. 137, no. 3, pp. 279–291, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Castillero, M. López-Menduiña, A. I. Martín, M. A. Villanúa, and A. López-Calderón, “Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1,” Journal of Endocrinology, vol. 210, no. 3, pp. 361–368, 2011. View at Google Scholar
  44. E. Jennische and C. M. Hall, “Expression and localisation of IGF-binding protein mRNAs in regenerating rat skeletal muscle,” APMIS, vol. 108, no. 11, pp. 747–755, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Jogie-Brahim, D. Feldman, and Y. Oh, “Unraveling insulin-like growth factor binding protein-3 actions in human disease,” Endocrine Reviews, vol. 30, no. 5, pp. 417–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. S. Pampusch, E. Kamanga-Sollo, M. E. White, M. R. Hathaway, and W. R. Dayton, “Effect of recombinant porcine IGF-binding protein-3 on proliferation of embryonic porcine myogenic cell cultures in the presence and absence of IGF-1,” Journal of Endocrinology, vol. 176, no. 2, pp. 227–235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Crossland, D. Constantin-Teodosiu, S. M. Gardiner, D. Constantin, and P. L. Greenhaff, “A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle,” The Journal of Physiology, vol. 586, no. 22, pp. 5589–5600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Schakman, M. Dehoux, S. Bouchuari et al., “Role of IGF-I and the TNFα/NF-κB pathway in the induction of muscle atrogenes by acute inflammation,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 303, no. 6, pp. E729–E739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Alami, V. Page, Q. Yu et al., “Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models,” Growth Hormone and IGF Research, vol. 18, no. 6, pp. 487–496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Cortés-Sempere, M. P. De Miguel, O. Pernía et al., “IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer,” Oncogene, vol. 32, no. 10, pp. 1274–1283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. S. S. Y. Chan, S. M. Twigg, S. M. Firth, and R. C. Baxter, “Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 12, pp. 6588–6595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Castillero, M. P. Nieto-Bona, C. Fernández-Galaz et al., “Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy,” American Journal of Physiology—Endocrinology and Metabolism, vol. 300, no. 5, pp. E790–E799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. Z. Hu, H. Wang, H. L. In, J. Du, and W. E. Mitch, “Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice,” The Journal of Clinical Investigation, vol. 119, no. 10, pp. 3059–3069, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. S. C. Bodine, T. N. Stitt, M. Gonzalez et al., “Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo,” Nature Cell Biology, vol. 3, no. 11, pp. 1014–1019, 2001. View at Publisher · View at Google Scholar · View at Scopus